Rain Enhancement Technologies Holdco, Inc.
RAINW
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.71M
Close$
Share Statistics
| Market cap | $7.71 Million |
|---|---|
| Enterprise Value | $7.79 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 96.76% |
|---|---|
| Return on Assets | -487.41% |
| Return on Invested Capital | 93.64% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 741.47 |
| Enterprise Value to EBIT | -0.74 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Rain Therapeutics Inc
4 employees
CEO: Randall Seidl Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes usi...